Balyasny Asset Management
PDLI

Balyasny Asset Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Balyasny Asset Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-18,200
Closed -$54K – 2395
2018
Q1 		$54K Buy
18,200
+5,300
+41% +$14.5K ﹤0.01% 1860
2017
Q4 		$35K Buy
+12,900
New +$39.6K ﹤0.01% 2021
2017
Q2 		– Sell
-100,017
Closed -$227K – 1969
2017
Q1 		$227K Buy
100,017
+56,717
+131% +$125K ﹤0.01% 1461
2016
Q4 		$92K Buy
43,300
+11,968
+38% +$33.4K ﹤0.01% 1318
2016
Q3 		$105K Sell
31,332
-14,100
-31% -$44.8K ﹤0.01% 918
2016
Q2 		$143K Sell
45,432
-17,680
-28% -$59K ﹤0.01% 1072
2016
Q1 		$210K Buy
63,112
+29,590
+88% +$92.2K ﹤0.01% 1115
2015
Q4 		$119K Buy
+33,522
New +$140K ﹤0.01% 1154

Other funds holding PDLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return